TECHNOLOGY PLATFORMS

From drug discovery to clinical development and global licensing

Building on its expertise in vascular disease research, Curacle develops small-molecule drugs and antibody therapeutics tailored to the characteristics of each disease and its therapeutic goals. Through its proprietary SOLVADYS® platform and collaborative research using MabTics’ EAGLES® platform, Curacle discovers competitive drug candidates and advances clinical development and global out-licensing.

CURACLE PROPRIETARY PLATFORM

SOLVADYS®

Small-molecule discovery focused on improving endothelial function

SOLVADYS® recreates disease-relevant conditions in human endothelial cells to identify compounds that improve impaired function.

Compounds are designed and refined using multiple readouts, including barrier function and inflammatory responses. Efficacy and mechanism studies in disease models, together with pharmacokinetic assessments, guide candidate selection.

Conceptual small-molecule and endothelial-cell illustration
  1. 01Model disease conditions
  2. 02Identify functional hits
  3. 03Optimize compounds
  4. 04Validate efficacy & mechanism

Global clinical development achievements

  • Receipt of the U.S. Phase 2a clinical study report (CSR) for CU06 (Rivasterat) in diabetic macular edema (2024.04).

Continued discovery of new candidates

  • CU71: Discovery of a candidate for neurodegenerative diseases.
  • CU72: Discovery of a candidate for idiopathic pulmonary fibrosis.

Government R&D support and research expansion

  • CU72: Selection of AI-enabled collaborative research for a 2026 government R&D project.
  • CP02: Selection of the companion-animal medicine for the Jeonbuk next-generation veterinary medicines regulatory-free special zone project.

MABTICS PLATFORM · CO-DEVELOPMENT WITH CURACLE

EAGLES®

Antibody development powered by extensive libraries and precision engineering

EAGLES® is MabTics’ platform for identifying antibodies from diverse libraries and engineering their function and structure for therapeutic applications.

Curacle and MabTics combine vascular disease expertise with antibody technologies to co-develop candidates that activate protective vascular signals or inhibit disease-driving signals.

Conceptual antibody and cell-surface receptor illustration
> 2.5 × 1011

Extensive antibody libraries

Library diversity exceeding 2.5 × 10¹¹ supports antibody discovery across multiple targets.

Function-driven selection

Evaluation goes beyond target binding to assess functions such as signal activation and inhibition.

Mono-, bi- and multispecific formats

Combines mechanisms and optimizes antibody structure and function.

  1. 01Discover antibodies
  2. 02Screen for function
  3. 03Engineer & optimize
  4. 04Validate candidates

Global licensing of MT-103

  • The bispecific retinal-disease candidate MT-103 (MMT-205) was licensed to US-based Memento Medicines in 2026.

Government R&D project selections

  • KDDF projects: MT-101 (2023), MT-103 (2024) and MT-201 (2026).
  • Ministry of SMEs and Startups project: MT-501 (2026).

Expansion of the antibody pipeline

  • Co-development of MT-101, MT-103, MT-105, MT-201 and MT-202 across kidney, retinal, inflammatory bowel and thrombotic diseases.